Menu
At the intersection of health and technology, HeartFlow leverages advanced technology and applies it to healthcare. With the HeartFlow FFRCT Analysis, HeartFlow is driving towards a new standard of care for the diagnosis and management of coronary artery disease – the number one killer worldwide.
Learn more about our technology in this short video or preview the HeartFlow Analysis by downloading our mobile app (available on iOS in North America and the UK only) or clicking below.
Real-world study reveals significant reduction in all-cause and cardiovascular mortality.
A real world, multi-center, retrospective study including more than 90,000 patients assessing at a national level the incremental impact of adding FFRCT to a CCTA-first diagnostic paradigm for evaluating and managing coronary artery disease (CAD). The study was conducted in England and was funded by UK Medical Research Council (MRC).
+
The path to diagnosing coronary artery disease (CAD) hasn’t always been clear or reliable.1,2 Until now. The pathway begins with a CCTA. If the physician sees disease, the CCTA images are sent to HeartFlow, where AI algorithms, computational fluid dynamics and trained analysts create the HeartFlow FFRCT Analysis. This personalized, color-coded 3-D model of a patient’s coronary arteries provides functional information about each blockage.
+
The path to diagnosing coronary artery disease (CAD) hasn’t always been clear or reliable.1,2 Until now. The pathway begins with a CCTA. If the physician sees disease, the CCTA images are sent to HeartFlow, where AI algorithms, computational fluid dynamics and trained analysts create the HeartFlow FFRCT Analysis. This personalized, color-coded 3-D model of a patient’s coronary arteries provides functional information about each blockage.
| SPECT | Stress Echo | Coronary CTA | HeartFlow Analysis | |
|---|---|---|---|---|
|
Common Questions |
 |
 |
 |
 |
|
Does my patient have CAD? |
X |
X |
X |
X |
|
Do the vessels have plaque? |
|
|
X |
X |
|
Where are the coronary artery specific stenoses? |
|
|
X |
X |
|
Is there possible ischemia? |
X |
|
X |
X |
|
What are the lesion-specific functional limitations? |
|
|
|
X |
|
Which vessels may benefit from PCI/CABG/OMT? |
|
|
|
X |
|
Is prognostic information provided? |
X |
X |
X |
X |
|
Diagnostic Performance* |
|
|
|
|
|
Disadvantages1, 2-6 |
Low sensitivity; high rate of false negatives; higher radiation exposure; lacks anatomic data
|
Often requires additional testing; lacks anatomic data
|
High sensitivity can lead to overutilization of invasive testing when not paired with functional information
|
Requires CCTA; Currently not as well known as other tests
|
|
Advantages1, 2-6 |
Accessible; high specificity; standard of care
|
Accessible; no radiation
|
Better long-term outcomes than usual care testing; lower radiation; provides anatomic data
|
More accurate than other non-invasive tests; provides anatomic and functional information; lower radiation; single patient visit
|
* Diagnostic performance of SPECT, CCTA and FFRCT evaluated in a head-to-head comparison for the identification of ischemia.
| SPECT | Stress Echo | Coronary CTA | HeartFlow Analysis |
| HeartFlow Analysis | |
|---|---|
|
Common Questions |
 |
| Stress Echo | |
|---|---|
|
Common Questions |
 |
| Coronary CTA | |
|---|---|
|
Common Questions |
 |
| SPECT | |
|---|---|
|
Common Questions |
 |
|
Does my patient have CAD? |
X |
|||
|
Do the vessels have plaque? |
|
|||
|
Where are the coronary artery specific stenoses? |
|
|||
|
Is there possible ischemia? |
X |
|||
|
What are the lesion-specific functional limitations? |
|
|||
|
Which vessels may benefit from PCI/CABG/OMT? |
|
|||
|
Is prognostic information provided? |
X |
|
Does my patient have CAD? |
X |
|||
|
Do the vessels have plaque? |
|
|||
|
Where are the coronary artery specific stenoses? |
|
|||
|
Is there possible ischemia? |
X |
|||
|
What are the lesion-specific functional limitations? |
|
|||
|
Which vessels may benefit from PCI/CABG/OMT? |
|
|||
|
Is prognostic information provided? |
X |
|
Does my patient have CAD? |
X |
|||
|
Do the vessels have plaque? |
X |
|||
|
Where are the coronary artery specific stenoses? |
X |
|||
|
Is there possible ischemia? |
|
|||
|
What are the lesion-specific functional limitations? |
|
|||
|
Which vessels may benefit from PCI/CABG/OMT? |
|
|||
|
Is prognostic information provided? |
X |
|
Does my patient have CAD? |
X |
|||
|
Do the vessels have plaque? |
X |
|||
|
Where are the coronary artery specific stenoses? |
X |
|||
|
Is there possible ischemia? |
X |
|||
|
What are the lesion-specific functional limitations? |
X |
|||
|
Which vessels may benefit from PCI/CABG/OMT? |
X |
|||
|
Is prognostic information provided? |
X |
|
Diagnostic Performance* |
|
|
Disadvantages1, 2-6 |
Low sensitivity; high rate of false negatives; higher radiation exposure; lacks anatomic data
|
|
Advantages1, 2-6 |
Accessible; high specificity; standard of care
|
|
Diagnostic Performance* |
|
|
Disadvantages1, 2-6 |
Often requires additional testing; lacks anatomic data
|
|
Advantages1, 2-6 |
Accessible; no radiation
|
|
Diagnostic Performance* |
|
|
Disadvantages1, 2-6 |
High sensitivity can lead to overutilization of invasive testing when not paired with functional information
|
|
Advantages1, 2-6 |
Better long-term outcomes than usual care testing; lower radiation; provides anatomic data
|
|
Diagnostic Performance* |
|
|
Disadvantages1, 2-6 |
Requires CCTA; Currently not as well known as other tests
|
|
Advantages1, 2-6 |
More accurate than other non-invasive tests; provides anatomic and functional information; lower radiation; single patient visit
|
Click to expand
Click to collapse
Click to expand
* Diagnostic performance of SPECT, CCTA and FFRCT evaluated in a head-to-head comparison for the identification of ischemia.
Click to collapse
Physicians can use the HeartFlow Analysis for any clinically stable symptomatic patient with CAD. The pathway requires access to a standard CT scanner and an institution that offers the HeartFlow Analysis. Find a center near you using our finder tool or contact your local HeartFlow representative.
Within hours, physicians can receive the HeartFlow Analysis, which is available on desktop and mobile.
Physicians can use the HeartFlow Analysis for any clinically stable symptomatic patient with CAD. The pathway requires access to a standard CT scanner and an institution that offers the HeartFlow Analysis. Find a center near you using our finder tool or contact your local HeartFlow representative.
Within hours, physicians can receive the HeartFlow Analysis, which is available on desktop and mobile.
REFERENCES
HeartFlow Analysis is consisted of four main functions; FFRCT, Planner, Roadmap, and Plaque. All four functions are cleared for clinical use in the United States, Bahrain, Israel, and United Arab Emirates. Only FFRCT and Planner functions are cleared cleared for clinical use in Europe, United Kingdom, Australia, Canada, and Japan. Please see HeartFlow Analysis Indications for Use and Instructions for Use for more information.
© 2024 HeartFlow, Inc. | HeartFlow and the HeartFlow logo are registered trademarks of HeartFlow, Inc. Additionally, RoadMap is claimed as a trademark of HeartFlow, Inc. www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041
*Required fields
If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.
*Required fields
オンライン提出フォームから研究助成金を申請してください。
HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用することを目的としています。
ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.
さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.
The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.
For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.
If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.Please use our online submission form on the Clinical Research Page to apply for research grants.
Thank you for your interest!
Executive Vice President and Chief Medical Officer
Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
He received his A.B. from Harvard College and his M.D. from Harvard Medical School.
本情報は日本国内の医療関係者を対象とした情報提供サイトです。
一般の方に対する情報提供を目的としたものではございません。
あなたは医療関係者ですか？